How to Determine Unresectability in Hilar Cholangiocarcinoma

hCCA is a biologically aggressive disease for which the only curative treatment remains surgical resection. The intersection of the patient's physical reserve, locoregional tumor involvement of porta hepatis structures, predicted resection requirements with resul-tant FLR, and accurate assessment of metastatic disease heavily influence patient selection and their ultimate ability to undergo surgical resection. A multidisciplinary, holistic, and individualized approach to patient selection is critical to accurately deter-mine resectability and optimize clinical outcomes for patients with hCCA.

Automated summary

hCCA is a biologically aggressive disease and surgical resection is the only curative treatment. Factors such as patient's physical condition, tumor involvement, residual liver volume, and assessment of metastatic disease heavily influence the feasibility of surgical resection. A multidisciplinary, holistic, and individualized approach is critical for accurately determining resectability and optimizing clinical outcomes for patients with hCCA.